Illinois State Resource Center

Chicago Skyline

Our Mission

ALF promotes education, advocacy, support services and research for the prevention, treatment and cure of liver disease. ALF Great Lakes provides a wide variety of these services including information and referral, education programs, support groups, exciting fundraising events, and an array of volunteer opportunities.

For help with issues related to liver disease, please contact our Help Center by using the Live Chat feature at the bottom of your browser window or call us at (800) 465-4837 Monday through Friday 9 am to 5 pm Eastern Time or by email at info@liverfoundation.org.

COVID-19

Illinois Department of Public Health

Liver Screenings

Hepatitis C Screenings

Interested in free hepatitis C screenings in an area near you? Here are upcoming dates and locations of hepatitis C screenings in the area! Know your status!

Learn more about testing and resources in your area with this CDC database of free screenings by zip code. Click here.

Weekly Testing by M.A.D.E (Making a Daily Effort)

Mondays, 9am – 2pm

  • 8000 S. Cottage Grove

Tuesdays, 9am – 2pm

  • 5343 S. Western

Wednesdays and Thursdays, 9am – 2pm

  • 5959 S Ashland

Weekly Testing by BHC (Brothers Health Collective)

Tuesdays, Thursdays, Saturdays, 10 am – 2pm

  • Matthew House Chicago, 3722 S Indiana Ave

4th Fridays of the month, 10 am – 2 pm

  • Chicago Women’s AIDS Project 6363, N Broadway St

Saturdays, 9 am – 3 pm

  • 2517 S Archer Ave

The Night Ministry

The Night Ministry Mobile Screening Van (Note: the Night Ministry only serves 1. Those experiencing homelessness or unstable housing, 2. MSM of color)

Sunday

  • Humboldt Park (Division & California) 4:00 – 6:00 pm
  • Uptown (Wilson & Hazel) 6:30 -8:30 pm

Monday

  • South Shore (Jeffery & 71st) 7:00 – 9:00 pm
  • Pilsen (Cermak & Loomis) 9:30 – 11:30 pm

Tuesday

  • Back of the Yards (54th & Halsted) 7:00 – 9:00 pm
  • Humboldt Park (Division & California) 9:30 – 11:30 pm

Wednesday

  • South Shore (Jeffery & 71st) 7:00 – 9:00 pm
  • Uptown (Wilson & Hazel) 9:45 -11:45 pm

Thursday

  • Back of the Yards (54th & Halsted) 7:00 – 9:00 pm
  • Pilsen (Cermak & Loomis) 9:30 – 11:30 pm

Support Groups

Support groups provide a place for individuals affected by a similar condition or circumstance to provide and receive support and share their experiences.

Not all support groups are facilitated by a medical professional. Some support groups are facilitated by 3rd party organizations and individuals in this region.

ALF also has identified virtual online support groups you can take advantage of by visiting this page.

Arlington Heights

Northwest Community Healthcare
Center for Specialty Medicine, LCI
Mallard Room
800 West Central Road
Arlington Heights, IL

Hep C outreach is a support group for people and/or family and friends of people with Hepatitis C. The group can provide emotional support and share information about the disease with people who have or have had Hepatitis C.

Meets: First Monday of each month, 7:00 – 9:00 PM
Phone: 847-253-8866
Emaildeb72157@comcast.net

Contact Debra Panarese for more information.

Cambridge

Alpha-1 Foundation Support Group – Open Arms Alpha-1 Support Group

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org.

Contact
Jackie English and Deb Burwell (Support Group Leaders)

For more information
https://www.alpha1.org/alphas-friends-family/support/sg/

Phone
309-714-9427
309-863-0888

Web
www.alpha1.org

Email
jackieenglish@live.com
openarmsforalpha1@gmail.com

Chicago

Andersonville Support Group

First Evangelical Church
5255 North Ashland Avenue
Chicago, IL

Meets the 1st and 3rd Wednesday of each month. Please visit the website above for more information.

Meets: 7:00PM

Contact Terry Enright for more information.

Liver Support Group at Rush University Medical Center

937 North Atrium Classroom
1653 West Congress Pkwy
Chicago, IL

This support group is for patients and their families who are waiting or recovering from liver transplant at Rush. The support group shares stories with one another and is facilitated by a chaplain and social worker. Call Carla Albergo, LSW, (312) 563-4223, with any questions.

Meets: Thursdays 3pm

New Hepatitis C Support Group Hosted by the University of Chicago and ALF

Crown Plaza Hotel
160 East Huron
University of Chicago Clinic
9th floor
Chicago, IL 60611

Meets: January 10, 2013
Phone: 312-377-9030
Email: jdominguez@liverfoundation.org

Contact Jacqueline Dominguez (American Liver Foundation) for more information.

Transplant Support Group

47 W Polk Street
Suite 100-140
Chicago, IL

Phone: 800-494-4527

East Moline

New Beginnings – A support group for individuals living with liver disease

Phone: 309-792-1485

Contact Martin Schmidt for more information.

McHenry

Transplant Support Group of Northern Illinois

Northern Illinois Medical Center
4201 Medical Center Drive
McHenry, IL 60050

Phone: 815-477-9528

Naperville

Organ Transplant Support, Inc.

PO Box 471
Naperville, IL 60566

Contact: Carol Olash, President
Phone: 630-527-8640
Email: organtransplantsupport@gmail.com
Websiteorgantransplantsupport.org

Springfield

Central Illinois Transplant Support Group

4001 Sandhill Road, #124
Springfield, IL 62702

Phone: 217-899-8036

Hepatitis C Teleconferences on Tuesday nights

Listen to speakers discuss various hepatitis C related topics, followed by a question and answer session, and time to “chat.” Teleconference is free and confidential.

Meets: Tuesday from 7pm to 9pm CST

Winfield

Support Group

Central DuPage Hospital
25 North Winfield Road
Winfield, IL

Provides support for individuals and their family members who have experienced liver disease regardless of type or stage.

Meets: First Thursday of each month, 7:00 – 8:30 PM
Phone: 630.399.5709
Emailmth2@att.net

Contact Kelly Hofmann for more information.

Clinical Trials

Find a Clinical Trial anywhere…

Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications. Start your search here to find clinical trials that need people like you.

HCC

STUDY SPONSOR: Glycotest
PI: Laura Kulik, M.D.
COORDINATOR: Kim 312-694-1293 k-sipich@northwestern.edu

STUDY TITLE: Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

INCLUSION (Controls):INCLUSION (Cases):
Cirrhosis (Childs Pugh A-B8)No evidence of HCC on imagingTreatment naïve HCCLI-RADS LR-5 or OPTN 5 CT or MRI criteria (all lesions must exhibit arterial phase hyper-enhancement), or histologic evidence

Alcoholic Hepatitis

PI: Dr. Maddur
COORDINATOR: Jeanne, phone 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE: Liver Transplantation for Severe Acute Alcoholic Hepatitis

OBJECTIVE: The purpose of this study is to assess the outcomes of liver transplantation in selected patients with severe acute alcoholic hepatitis that is refractory to medical therapy.

INCLUSION:EXCLUSION:
Patients who present with their first episode of alcoholic hepatitis as the first manifestation of liver disease Age ≥18 yearsPatients with a Maddrey Discriminant Function of > 32Medical or surgical contraindication to liver transplantationPatients with a history of other alcohol related illnesses prior to presentation including alcohol induced pancreatitis and alcohol withdrawal.Concomitant pathologies (i.e alpha 1 antitrypsin disease, Hepatitis B, C, PBC, PSC, AIH, Wilsons, HIV detectable

STUDY SPONSOR: DURECT

PI: Dr. Flamm
COORDINATOR: Kim, phone 312-694-1293, k-sipich@northwestern.edu

STUDY TITLE: A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

OBJECTIVE: Evaluate the safety and efficacy, as determined by 90-day mortality, of DUR-928 in subjects with alcoholic hepatitis (AH) with pre-treatment Maddrey’s DF score ≥ 32 and MELD scores 21-30

INCLUSION:EXCLUSION:
Currently hospitalizedOnset of jaundice within prior 8 weeks(MELD) score: 21-30Patients with a Maddrey Discriminant Function of > 32Active InfectionAlcohol withdrawal symptomsAKI or Hepatorenal Syndrome

Primary Sclerosing Cholangitis (PSC)

STUDY SPONSOR: Gilead
PI: Dr. Flamm
COORDINATOR: Jeanne, phone 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

MOA: GS-9674 is a potent Farnesoid X (FXR) agonist. FXR receptor is a master regulator of bile acid homeostasis, controls inflammatory, glucose, and lipid metabolic pathways, and is prevalent in metabolically active tissues, liver, kidney, and intestine.

INCLUSION:EXCLUSION:
Definite PSC diagnosisAge 18-70 yearsLiver biopsy within 6 months showing F0-F3Diagnosis of large duct PSC based on cholangiogram (MRCP, ERCP, or PTC)History or presence of other concomitant liver diseasesCirrhosisLiver transplantPresence of a percutaneous drain or biliary stent

Cirrhosis

PI: Dr. Levitsky; Sub-I: Dr. Mazumder

COORDINATOR: Cynthia Padilla, 312-926-4260, cynthia.padilla@northwestern.edu

STUDY TITLE: Non-invasive Assessment of Cardiac Filling Pressures via Valsalva Response as Measured by Finger Photoplethysmography in Cirrhosis

OBJECTIVE 1 (validation of device against gold standard): We hypothesize that the PAR measured by PPG will be correlated with invasive measures of cardiac filling pressures after adjustment for appropriate demographic, serologic, and echocardiographic covariates.

OBJECTIVE 2 (prediction of invasive measures of cardiac filling pressures with multivariable model building): We hypothesize clinically significant cardiac filling pressures can be predicted via multivariable model building using non-invasively collected covariates in this study.

BLOOD PRESSURE PILOT

PI: Lisa VanWagner

Coordinator: Cynthia Padilla, phone: 312-926-4260, cynthia.padilla@northwestern.edu

Study Title: Pilot study to assess the feasibility and clinical utility of home and 24-hour ambulatory blood pressure monitoring in liver transplant recipients

Objectives:

  1. To define the true burden of hypertension in liver transplant recipients (LTRs) using well measured blood pressure (BP) techniques, including seated in-office BP, home BP monitoring (HBPM) and ambulatory BP monitoring (ABPM). We hypothesize that in office BP measurement underestimates true prevalence of hypertension when BP is assessed by HBPM or ABPM in LTRs.
  2. To assess the feasibility and tolerability of HBPM versus ABPM in LTRs. We hypothesize that HBPM and ABPM are both feasible in LTRs but that HBPM will be better tolerated by LTRs

Inclusion:

  • Age ≥ 18
  • Liver transplant recipient

Exclusion:

  • Prisoners
  • Pregnant women
  • Individuals unable to provide consent
  • Individuals with dual heart transplants

PORTAL HYPERTENSION

PI: Dr. Lisa VanWagner; Sub-I: Dr. Justin Boike

COORDINATOR: Cynthia Padilla, 312-926-4260, cynthia.padilla@northwestern.edu

STUDY TITLE: Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the management of portal hypertension – A 5-year longitudinal observational study of patients with cirrhosis undergoing TIPS placement

Objectives:

To prospectively collect clinical information on the use and outcomes associated with contemporary real-world practice of Transjugular Intrahepatic Portosystemic Shunts (TIPS). The goals of the consortium are to answer key clinical questions related to contemporary patterns of TIPS usage as well as clinical outcomes.  This database will serve to inform and answer clinically related questions about the optimization of TIPS use and management.

Study Endpoints:

  • Clinical outcomes of TIPS related to the initial indication
  • Survival data up to at least 1 year after TIPS placement
  • Complications related to underlying liver disease before and after TIPS

Inclusion and Exclusion Criteria

Inclusion criteria:

  • Subjects over the age of 18 able to provide consent or have a surrogate decision maker provide consent in the event the subject is unable to consent due to a transient clinical condition.

Exclusion criteria:

  • Minors under the age of 18 at the time of enrollment
  • Subjects undergoing TIPS placement as part of an investigational study outside of usual clinical care
  • Subjects unable to provide consent

ALTA Sub-Study – TIPS on Cardiac Function

STUDY SPONSOR: Gore

PI: Lisa VanWagner

COORDINATOR: Cynthia Padilla, phone: 312-926-4260, cynthia.padilla@northwestern.edu

STUDY TITLE: Impact of Transjugular Intrahepatic Portosystemic Shunting (TIPS) on Cardiac Function in Patients with Portal Hypertension

OBJECTIVES:

  1. To describe the distribution and patterns of echocardiogram-derived indices of cardiac mechanics (e.g., strain measures) and circulating cardiac biomarkers (e.g., hs-troponin and NT-pro BNP) following TIPS.
  2. To describe change over time in echo-derived markers of cardiac mechanics and circulating cardiac biomarkers following TIPS.
  3. To identify patterns of cardiac mechanics and circulating cardiac biomarkers among TIPS recipients that are associate

INCLUSION:

  • Consented for the ALTA study
  • Able to consent or has a legally authorized representative to provide consent

EXCLUSION:

  • Undergoing TIPS placement as part of an investigational study outside of usual clinical care

 Hepquant Substudy – TIPS on Hepatic Encephalopathy

PI: Justin Boike

COORDINATOR: Jeanne Gottstein, phone: 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE: HepQuant to predict hepatic encephalopathy in patients who receive transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites – a pilot study

OBJECTIVES:

  1. To determine if a novel blood test, HepQuant® SHUNT Test, can predict patients at risk for developing hepatic encephalopathy after placement of a transjugular intrahepatic portosystemic shunt (TIPS).
  2. To describe the difference in liver blood flow shunting as assessed by HepQuant® SHUNT Test before and after TIPS.

INCLUSION:

  • Subjects participating in the ALTA registry (STU00208288)
  • Subjects over the age of 18 able to provide consent
  • Subjects undergoing initial TIPS procedure for the primary indication of treatment of ascites

EXCLUSION:

  • Undergoing TIPS placement as part of an investigational study outside of usual clinical care

NASH

STUDY SPONSOR: VIKING
PI: Dr. Mary Rinella
COORDINATOR: Jeanne Gottsteinphone 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE: A phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of vk2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with biopsy proven non-alcoholic steatohepatitis with fibrosis.

MOA: VK2809 is being developed for the treatment of NASH. A safe, liver-directed THR-β agonist.

INCLUSION:EXCLUSION:
Males or females ≥ 18 years oldMRI-PDFF fat fraction ≥8% done during screening periodLiver biopsy NAS score ≥4, Fibrosis 2-3History of significant alcohol consumptionWeight change > 5% within 6 months prior to liver biopsyType 1 diabetes patientsHistory of bariatric surgery or intestinal bypass surgeryPatients with decompensated diabetes (HbA1c >9.0%)

STUDY SPONSOR: Enanta
PI: Dr. Mary Rinella
COORDINATOR: Jeanne Gottsteinphone 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE: A PHASE 2b RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING SAFETY AND EFFICACY OF EDP-305 IN SUBJECTS WITH LIVER-BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) (ARGON-2)

MOA: EDP-305 is a farnesoid X receptor (FXR) agonist being investigated by Enanta Pharmaceuticals, Inc. (Enanta) as a potential treatment for Nonalcoholic Steatohepatitis (NASH) with liver fibrosis.

INCLUSION:EXCLUSION:
Males or females ≥ 18 years old(NAS) of 4 or greater with a score of at least 1 in each component of the, fibrosis 2-3 on biopsy History of significant alcohol consumptionMELD >12Subjects with clinically or otherwise documented cardiovascular or cerebrovascular disease including clinically significant anomalies of rhythm or pattern of ECGUse of a new fibrate regimen from 3 months prior to ScreeningPatients with decompensated diabetes (HbA1c >9.5%) 

STUDY SPONSOR: NGM
PI: Dr. Rinella
COORDINATOR: Jeanne 312-694-0264 or Kim 312-694-1293, j-gottstein@northwestern.eduk-sipich@northwestern.edu

STUDY TITLE: Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Doubleblind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)

MOA: By engaging both FGFR4 and FGFR1c pathways to reduce bile acid toxicity and lipotoxicity, and to improve insulin sensitivity, NGM282 has demonstrated robust anti-steatotic, anti-inflammatory and anti-fibrotic activities in multiple animal models of NASH

INCLUSION:EXCLUSION:
Adults from 18 to 75 yearsTotal liver fat ≥ 8%, MRI-PDFFLiver biopsy NAS score ≥4, CirrhosisStatin use based on the following criteria for statin-naïve or statin-experienced at Screening:Statin naïve is defined as no statins within 3 months prior to Screening.Statin Experienced is defined as administration of < 50% of the maximal dose of current statin therapyClinically significant acute or chronic liver disease of an etiology other than NASHMELD score > 12No evidence of varices on EGDType 1 diabetes patients.Any contraindication or inability to obtain an MRI

STUDY SPONSOR: MADRIGAL 11
PI: Dr. Mary Rinella
COORDINATOR: Kim Sipichphone 312-694-1293, k-sipich@northwestern.edu

STUDY TITLE: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

MOA: MGL-3196 is being developed for the treatment of NASH and for potential use in hypercholesterolemia/dyslipidemia. A safe, liver-directed THR-β agonist.

INCLUSION:EXCLUSION:
Males or females ≥ 18 years oldMRI-PDFF fat fraction ≥8% done during screening periodLiver biopsy NAS score ≥4, Fibrosis 2-3Estimated glomerular filtration rate (GFR) ≥45History of significant alcohol consumption.Regular use of drugs historically associated with NAFLD, which include, but are not limited, to the following: amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens, anabolic steroids, valproic acid.Type 1 diabetes patientsHistory of bariatric surgery or intestinal bypass surgeryPatients with decompensated diabetes (HbA1c >9.0%)

STUDY SPONSOR: MADRIGAL 14
PI: Dr. Mary Rinella
COORDINATOR: Kim Sipichphone 312-694-1293, k-sipich@northwestern.edu

STUDY TITLE: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with

Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

MOA: MGL-3196 is being developed for the treatment of NASH and for potential use in hypercholesterolemia/dyslipidemia. A safe, liver-directed THR-β agonist.

INCLUSION:EXCLUSION:
Males or females ≥ 18 years oldMRI-PDFF fat fraction ≥8% done during screening periodLiver biopsy NAS ≥4, steatosis ≥1, fibrosis stage 0 or 1A/1C with PRO-C3 <14 NAS <4 steatosis ≥1, with fibrosis stage ≤3 NAS ≥4, steatosis ≥1, fibrosis stage ≤3 without ballooningHistory of significant alcohol consumptionRegular use of drugs historically associated with NAFLD, which include, but are not limited, to the following: amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens, anabolic steroids, valproic acidType 1 diabetes patientsHistory of bariatric surgery or intestinal bypass surgeryPatients with decompensated diabetes (HbA1c >9.0%)

STUDY SPONSOR: Galmed
PI: Dr. Mary Rinella
COORDINATOR: Jeanne Gottsteinphone 312-694-0264, j-gottstein@northwestern.edu

STUDY TITLE:  A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) with Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol

MOA: Aramchol is the first in a new pharmacological class of fatty acid-bile acid conjugates (FABACs).

INCLUSION:EXCLUSION:
Males or females ≥ 18 years oldMRI-PDFF fat fraction ≥8% done during screening periodLiver biopsy NAS ≥4, steatosis ≥1, fibrosis stage 0 or 1A/1C with PRO-C3 <14 NAS <4 steatosis ≥1, with fibrosis stage ≤3 NAS ≥4, steatosis ≥1, fibrosis stage ≤3 without ballooningHistory of significant alcohol consumptionType 1 diabetes patientsHistory of bariatric surgery or intestinal bypass surgeryPatients with decompensated diabetes (HbA1c >9.0%)

Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis

Northwestern University

This study will test the effects of simvastatin in people with liver cirrhosis. Participants in this study will get either simvastatin or placebo, a pill that looks like the study drug but contains no medication. This will allow researchers to see if participants taking simvastatin show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have liver cirrhosis. We will enroll 80 participants.

Contact Kim Sipich at 312-694-1293 to obtain more information.

Related Links

Comer Children’s Hospital

(773) 702-1000

Digestive Health Services

(630) 434-9312

DuPage Medical Group

(630) 469-9200

Jesse Brown VA Medical Center

(312) 569-8387

John H Stroger Hospital

(312) 864-7630

Loyola University

(708) 216-8815

Lurie Children’s Hospital

(800) 543-7362

NorthShore University HealthSystem

(888) 364-6400

Northwestern Memorial Hospital

(312) 695-4077

Rockford Gastroenterology Associates

(815) 397-7340

Rush University

(888) 352-7874

Sherman Hospital

(800) 323-8622

University of Chicago

(888) 824-0200

University of Illinois, Chicago

(312) 949-9199

Diseases of the Liver

Government Organizations

Liver Disease Diets

Liver Transplant

Medical Terminology

Patient Organizations

Professional Organizations

Progression of Liver Disease

Student Resources

Additional Resources

State of Illinois Department of Insurance
Download brochure

In addition to the resources listed above in your state or district, ALF provides these resources that are available no matter where you are. Explore them now…

Last updated on September 20th, 2022 at 12:07 pm

cross linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram